Entero Therapeutics, Inc.

About Entero Therapeutics, Inc.

Entero Therapeutics is a clinical stage biopharmaceutical company focused on developing targeted, orally delivered therapies for gastrointestinal (GI) diseases.

Products & Services

Latiglutenase:A potentially first-in-class oral biotherapeutic designed to break up gluten and reduce symptoms of celiac disease.

Capeserod:A selective 5-HT4 receptor partial agonist being developed for multiple GI indications, including gastroparesis.

Adrulipase:A recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.

Specialties

Gastrointestinal (GI) disease therapies Oral biotherapeutics Celiac disease treatment Gastroparesis treatment Exocrine pancreatic insufficiency treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 1921315 MR: - FA: $1.9 Million FAN: 1921315	D: 2024-07-11 FD: 2024-07-11	-

Private Placement Latest

2024-07-11

$1.9M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jason Sawyer

CEO

A

Anna Skowron

Interim Chief Financial Officer

E

Edward J. Borkowski

Lead Independent Director

R

Richard Paolone

Director

E

Eric Corbett

Director

M

Mike Uppal

Director

View 6 more team members with Pro

Unlock Full Team Directory

Recent News